Napa IV Infusion 10 mg/ml

Napa Injection is a fast-acting paracetamol formulation manufactured by Beximco Pharmaceuticals Ltd. With a strength of 10 mg/ml, this intravenous solution effectively treats fever, headaches, postoperative pain, and inflammatory conditions. Priced at ৳150.00 per unit, it offers affordable pain management while adhering to strict quality standards.

This IV infusion inhibits prostaglandin synthesis via COX enzymes, providing analgesic and antipyretic effects. It’s particularly useful for patients unable to take oral medication. The injection format ensures rapid bioavailability, making it ideal for acute pain relief in hospital settings or emergency care.

Dosage varies by age: adults may receive 1-2 tablets every 4-6 hours (max 8/day), while pediatric doses depend on weight. For IV use, precise medical supervision is mandatory. Storage requires a cool, dark place away from children. Avoid combining with alcohol or enzyme-inducing drugs like phenobarbital to prevent liver toxicity.

Common LSI keywords like “Napa IV Infusion uses” and “Paracetamol alternatives” reflect its therapeutic versatility. Though generally safe, rare side effects include skin rashes or pancreatitis. Pregnant/lactating women should consult doctors despite its low-risk profile. Overdose risks liver damage – immediate N-acetylcysteine treatment is critical.

Explore more about generic paracetamol options and other pain management solutions. Trusted by healthcare professionals nationwide, Napa Injection remains a cornerstone in Bangladesh’s pharmaceutical landscape for effective, budget-friendly care.

Adults: 10 mg/mL strength, 1-2 vials (1000-2000 mg) every 4-6 hours. Pediatric dose: 15 mg/kg body weight. Reduce dose by 50% in severe hepatic/renal impairment. Administer IV infusion slowly over 15 minutes. Do not exceed 10 days without medical supervision.

Side effects of Napa are usually mild, though haematological reactions including thrombocytopenia, leucopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. Pancreatitis, skin rashes, and other allergic reactions occur occasionally.

Pregnancy Category B: Use under medical supervision. Excreted minimally in breast milk – considered safe during lactation. Avoid prolonged use.

Monitor liver/renal function in predisposed patients. Do not exceed 4g/24 hours. Avoid combinations with NSAIDs. Check infusion compatibility with saline before administration.

Pediatrics: Safe above 2 years. Geriatrics: No dose adjustment. Hepatic impairment: Reduce dose by 50%. Renal failure: Extend dosing interval if CrCl <30.

Liver damage is possible in adults who have taken 10 g or more of Napa. Ingestion of 5 g or more of Napa may lead to liver damage if the patient has following risk factors: If the patient is on long term treatment with Carbamazepine, Phenobarbitone, Phenytoin, Primidone, Rifampicin, St John’s Wort or other drugs that induce liver enzymes, or regularly consumes Ethanol in excess of recommended amounts, or is likely to be Glutathione deplete e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia.

Symptoms: Symptoms of Napa overdose in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, haemorrhage, hypoglycaemia, cerebral oedema and death. Acute renal failure with acute tubular necrosis, strongly suggested by loin pain, haematuria and proteinuria, may develop even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported. Immediate treatment is essential in the management of Napa overdose. Treatment with activated charcoal should be considered if the overdose has been taken within 1 hour. Plasma Napa concentration should be measured at 4 hours or later after ingestion (earlier concentrations are unreliable). Treatment with N-acetylcysteine may be used up to 24 hours after ingestion of Napa. However, the maximum protective effect is obtained up to 8 hours post-ingestion. The effectiveness of the antidote declines sharply after this time. If required the patient should be given intravenous N-acetylcysteine, in line with the established dosage schedule. If vomiting is not a problem, oral Methionine may be a suitable alternative for remote areas, outside hospital. Management of patients who present with serious hepatic dysfunction beyond 24 hours from ingestion should be discussed with the NPIS or a liver unit.